Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT07927283
RecruitingNCT07927283ClinicalTrials.gov record

Fulvic Acid Supplementation and Metabolic Syndrome

Metabolic Syndrome

THE QUICK READ

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type
Interventional
Phase
Not applicable
Age range
18 years - 65 years
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
60 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Fulvic acid is a naturally occurring compound derived from the decomposition of organic matter in soil over long periods. Fulvic acid complexes, such as MLG-50 (MLG-50® Mineral Logic, Kalamazoo, Michigan), offer a highly concentrated, water-soluble form of fulvic acid that contains over 70 trace minerals and elements. Our preclinical studies have found that a soil derived organic mineral complex rich in fulvic acid prevented the high fat diet induced hyperglycemia, endothelial dysfunction, liver injury, endotoxemia, and gut dysbiosis induced by high-fat feeding in rats. We propose to examine the efficacy of fulvic acid (both 50 mg and 100 mg daily for 12 weeks) in the mitigation of symptoms related to metabolic syndrome.

Read the full description

Clinical trials examining the efficacy of fulvic acid on health parameters are scarce. However, shilajit, a natural substance rich in fulvic acid, was shown to reduce triglycerides, cholesterol, and increase HDL cholesterol as well as antioxidant status in healthy college students (n=30) after 45 days of supplementation (2 g daily). However, this quasi-experimental trial did not randomize participants into experimental groups, and causality cannot be evaluated. A 2018 review of the peer-reviewed literature on the therapeutic potential of fulvic acid concluded that although the available research is minimal, there was 'substantial evidence' to pursue fulvic acid research for improving biomarkers linked to chronic inflammatory diseases.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

  • metabolic syndrome or prediabetes

Exclusion Criteria:

  • pregnant or nursing
  • multiple medications to treat obesity, heart disease, thyroid conditions, cancer
  • smokers
  • competing athletes
  • vegetarians
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Double masked
Fulvic acid 50

50 mg

Dietary Supplement: fulvic acid

Fulvic acid 100

100 mg

Dietary Supplement: fulvic acid

Placebo

cornstarch

Other: Placebo

fulvic acid DIETARY_SUPPLEMENT

50 mg

fulvic acid DIETARY_SUPPLEMENT

100 mg

Placebo OTHER

cornstarch

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

girth

Time frame: from enrollment to 6 week and to 12 week

waist circumference in cm

hypertension

Time frame: from enrollment to 6 week and to 12 week

diastolic and systolic blood pressure

hyperglycemia

Time frame: from enrollment to 6 week and to 12 week

fasting blood glucose

hypertriglyceridemia

Time frame: from enrollment to 6 week and to 12 week

fasting blood triglycerides

cholesterol

Time frame: from enrollment to 6 week and to 12 week

fasting blood HDL cholesterol

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

PBC 850 N 5th StreetPhoenix, Arizona, United StatesRecruiting

Study team and timeline

Lead sponsor
Arizona State University
Study start
Nov 6, 2026 Estimated
Primary completion
Nov 15, 2027 Estimated
Study completion
Nov 15, 2027 Estimated
First posted
Nov 10, 2026 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Carol Johnston, PhDCONTACTcarol.johnston@asu.edu6024963463
Karen Sweazea, PhDCONTACTkaren.sweazea@asu.edu4809656025
Official study title

Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026